Once-daily oral administration of dapagliflozin results in rapid and sustained glucosuria for 24 h in patients with T2D, inhibiting up to 40% of filtered glucose from reabsorption by the kidneys, for a glucose excretion rate of up to 3 g/h (≈70 g/d).9 The pharmacodynamic properties of dapagliflozin have translated into consistent improvements in glycemic control in a wide spectrum of patients with T2D, both as monotherapy and in combination with other oral antidiabetes drugs (OADs) and/or insulin.10 Here, INS is linked to type 2 diabetes mellitus.